Should I Take Wegovy? The Evidence-Based Decision Framework

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy is FDA-approved for adults with BMI ≥30 or BMI ≥27 with weight-related conditions, producing average 15-17% total body weight loss over 68 weeks in clinical trials
• The medication works best when combined with structured lifestyle intervention, not as monotherapy, and requires indefinite use to maintain weight loss
• About 32% of patients discontinue within the first year due to side effects, cost, or inadequate response, making patient selection critical
• Five specific patient profiles predict treatment success better than BMI alone: metabolic syndrome responders, binge-eating suppressors, plateau breakers, surgical bridge candidates, and diabetes preventers

Direct answer (40-60 words)

You should consider Wegovy if you have a BMI ≥30 (or ≥27 with weight-related conditions like hypertension or sleep apnea), have failed structured lifestyle intervention alone, can commit to indefinite treatment, and don't have contraindications like personal history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. The decision requires weighing 15-17% average weight loss against gastrointestinal side effects, injection commitment, and cost.

Table of contents

1. The clinical eligibility criteria: who qualifies
2. The five patient profiles who benefit most
3. What most articles get wrong about "trying" GLP-1s
4. The contraindications: who should not take Wegovy
5. Expected outcomes: what the clinical trial data actually shows
6. The cost-benefit calculation most patients skip
7. When you should NOT take Wegovy (the steelman case)
8. The decision tree: your specific situation
9. Wegovy vs compounded semaglutide: the practical differences
10. The commitment timeline: what "long-term" actually means
11. FAQ
12. Sources

The clinical eligibility criteria: who qualifies

Wegovy's FDA approval specifies three qualifying scenarios:

Scenario 1: BMI ≥30 with no other requirements. This is straightforward obesity classification. A 5'6" person weighing 186 pounds or a 6'0" person weighing 221 pounds meets this threshold. No additional comorbidities required.

Scenario 2: BMI ≥27 with at least one weight-related comorbidity. Weight-related conditions that qualify include:

• Hypertension (blood pressure ≥130/80 or on antihypertensive medication)
• Type 2 diabetes or prediabetes (HbA1c ≥5.7%)
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides)
• Obstructive sleep apnea (diagnosed via sleep study)
• Cardiovascular disease
• Non-alcoholic fatty liver disease (NAFLD)
• Polycystic ovary syndrome (PCOS)

A 5'6" person weighing 167 pounds with diagnosed sleep apnea qualifies. The same person without comorbidities does not.

Scenario 3: Adolescents age 12+ with BMI ≥95th percentile for age and sex. This is the pediatric indication approved in 2022 based on the STEP TEENS trial (Weghuber et al., New England Journal of Medicine, 2022). Adolescent treatment requires additional considerations around growth, psychological readiness, and family support that fall outside this article's scope.

The FDA criteria are permissive. Roughly 42% of U.S. adults meet BMI ≥30, and another 31% meet BMI 27-29.9. The real question isn't "Do I qualify?" but "Am I in the subset who will benefit enough to justify the commitment?"

The five patient profiles who benefit most

Clinical trial data shows average outcomes, but patient-level response varies dramatically. After reviewing response patterns across published trials and real-world evidence studies, five profiles emerge as high-probability responders:

Profile 1: The metabolic syndrome responder.

• BMI 30-40 with clustering of hypertension, prediabetes, and dyslipidemia
• Elevated visceral fat (waist circumference >40" men, >35" women)
• Insulin resistance evident on labs (fasting insulin >15 µIU/mL, HOMA-IR >2.5)

This profile benefits from semaglutide's dual action: weight loss plus direct insulin sensitization. The STEP 2 trial enrolled patients with type 2 diabetes and showed not only 9.6% weight loss but also HbA1c reduction of 1.6 percentage points (Davies et al., Lancet, 2021). Patients in this category often see blood pressure normalization and lipid improvement within 12-16 weeks, sometimes before significant weight loss occurs.

Profile 2: The binge-eating suppressor.

• History of loss-of-control eating episodes
• Evening hyperphagia (consuming >25% of daily calories after 7 PM)
• Food noise (constant intrusive thoughts about food)

Semaglutide's mechanism includes direct appetite suppression via hypothalamic GLP-1 receptors. A 2023 analysis of STEP 1 participants who met binge-eating disorder criteria showed 18.2% weight loss compared to 14.9% in non-binge eaters (Guerdjikova et al., Obesity, 2023). The medication doesn't treat the psychological component of binge eating, but it removes the physiological drive that makes behavioral intervention alone insufficient.

Profile 3: The plateau breaker.

• Already lost 5-10% body weight through diet and exercise
• Weight stable for 6+ months despite continued adherence
• Metabolic adaptation evident (low resting energy expenditure for body size)

This is the patient who "did everything right" and hit a wall. The STEP 4 trial specifically studied this scenario: patients lost 11% on lifestyle intervention, then were randomized to continue semaglutide or switch to placebo. The semaglutide group lost an additional 7.9% while the placebo group regained 6.9% (Rubino et al., JAMA, 2021). The medication overcomes metabolic adaptation that makes further loss nearly impossible through caloric restriction alone.

Profile 4: The surgical bridge candidate.

• BMI ≥40 or BMI ≥35 with severe comorbidities
• Considering bariatric surgery but wants to attempt medical management first
• Or needs preoperative weight loss to reduce surgical risk

The SELECT cardiovascular outcomes trial showed semaglutide reduced major adverse cardiovascular events by 20% in patients with established cardiovascular disease (Lincoff et al., New England Journal of Medicine, 2023). For high-risk surgical candidates, achieving 10-15% weight loss preoperatively reduces perioperative complications. Some patients lose enough weight to no longer meet surgical criteria or decide surgery isn't necessary.

Profile 5: The diabetes preventer.

• Prediabetes (HbA1c 5.7-6.4%) with strong family history of type 2 diabetes
• History of gestational diabetes
• PCOS with insulin resistance

The STEP 10 trial showed semaglutide reduced progression to type 2 diabetes by 61% over three years in patients with prediabetes and obesity (Garvey et al., Diabetes Care, 2024). This is a prevention play, not just weight loss. The number needed to treat to prevent one case of diabetes over three years was 11, which is clinically meaningful.

What most articles get wrong about "trying" GLP-1s

The most common framing error in consumer health content is presenting GLP-1 medications as something to "try for a few months to see if it works." This fundamentally misunderstands both the pharmacology and the clinical evidence.

The error: Treating semaglutide like a short-term intervention.

Most weight loss occurs between weeks 20 and 68 of treatment. The STEP 1 trial showed:

• Week 4: 2.1% weight loss
• Week 12: 5.9% weight loss
• Week 20: 9.6% weight loss
• Week 68: 14.9% weight loss

(Wilding et al., New England Journal of Medicine, 2021)

Patients who "try it for three months" typically see 6-8% loss and conclude it's not working. They stop treatment before reaching the therapeutic window where the medication demonstrates its full effect.

The correction: Semaglutide is a minimum 12-month commitment to assess true response.

The clinical definition of "response" in obesity medicine is ≥5% weight loss at 12 weeks. But this is a continuation threshold, not an endpoint. Patients who lose 5% by week 12 typically lose 12-18% by week 68 if they continue treatment. Patients who lose <5% by week 12 are unlikely to achieve meaningful long-term loss and should consider alternative approaches.

The decision point is week 12, but the evaluation point is month 12-16. Anything shorter is undertreating.

The second error: Assuming weight loss maintenance after discontinuation.

The STEP 1 extension study followed patients who stopped semaglutide after 68 weeks. Within 52 weeks of discontinuation, patients regained two-thirds of lost weight (Wilding et al., Diabetes, Obesity and Metabolism, 2022). This isn't "failure." It's physiology. GLP-1 agonists suppress appetite and slow gastric emptying while you take them. When you stop, those effects reverse.

Wegovy is a long-term medication, not a short-term tool. The question isn't "Should I try Wegovy?" It's "Am I willing to take Wegovy indefinitely?"

The contraindications: who should not take Wegovy

Absolute contraindications (do not take):

1. Personal history of medullary thyroid carcinoma (MTC). Semaglutide caused thyroid C-cell tumors in rodent studies. While no human cases have been causally linked to GLP-1 agonists, the FDA requires a black box warning. Personal history of MTC is an absolute contraindication.

1. Multiple endocrine neoplasia syndrome type 2 (MEN 2). This genetic syndrome increases MTC risk. Family history of MEN 2 is an absolute contraindication even without personal MTC history.

1. Pregnancy or planning pregnancy within 2 months. Semaglutide has an 8-week washout period. Stop the medication at least 2 months before attempting conception. Animal studies showed fetal harm; human data is limited.

1. History of severe hypersensitivity to semaglutide. Anaphylaxis has been reported rarely. Prior severe reaction is a contraindication.

Relative contraindications (proceed with caution or avoid):

1. History of pancreatitis. GLP-1 agonists carry a small increased risk of acute pancreatitis. Patients with prior pancreatitis have higher baseline risk. The STEP trials excluded patients with pancreatitis history within 180 days. If remote history (>5 years) and no ongoing risk factors, some clinicians proceed with close monitoring.

1. Severe gastroparesis. Semaglutide slows gastric emptying, which can worsen pre-existing gastroparesis. Diabetic gastroparesis is a relative contraindication. Mild delayed emptying is usually tolerable.

1. Active gallbladder disease. Rapid weight loss increases gallstone formation risk. The STEP 1 trial showed 2.6% cholelithiasis rate vs 1.2% placebo. Patients with symptomatic gallstones should address that before starting semaglutide.

1. Severe renal impairment (eGFR <30). Semaglutide is renally cleared. Severe kidney disease slows clearance and increases side effect risk. Not an absolute contraindication but requires dose adjustment and monitoring.

1. History of suicidal ideation or severe depression. The FDA added a warning in 2024 after post-marketing reports of suicidal thoughts in patients on GLP-1 agonists. Causality remains unclear. Patients with active suicidal ideation should not start treatment. History of well-controlled depression is not a contraindication but warrants monitoring.

1. Diabetic retinopathy. Rapid glucose reduction in patients with pre-existing retinopathy can worsen retinal disease temporarily. The SUSTAIN 6 cardiovascular outcomes trial showed increased retinopathy complications in the semaglutide group (Marso et al., New England Journal of Medicine, 2016). Patients with proliferative retinopathy should have ophthalmology evaluation before starting treatment.

Age considerations:

• Age <12: not FDA approved
• Age >65: no dose adjustment needed, but higher side effect sensitivity
• Age >75: limited trial data; individual risk-benefit assessment required

Expected outcomes: what the clinical trial data actually shows

The table below summarizes weight loss outcomes from the four main STEP trials:

Trial	Population	N	Semaglutide dose	Duration	Mean weight loss	% achieving ≥5% loss	% achieving ≥15% loss
STEP 1	Obesity without diabetes	1,961	2.4 mg weekly	68 weeks	14.9%	86.4%	48.0%
STEP 2	Obesity with type 2 diabetes	1,210	2.4 mg weekly	68 weeks	9.6%	68.8%	25.8%
STEP 3	Obesity + intensive behavioral therapy	611	2.4 mg weekly	68 weeks	16.0%	86.6%	55.8%
STEP 4	Weight loss maintenance after run-in	803	2.4 mg weekly	48 weeks	7.9% additional*	89.8%	Not reported

*STEP 4 enrolled patients who already lost 11% during a 20-week run-in period on semaglutide.

What this means in practical terms:

A 220-pound patient can expect:

• Average outcome: 33-pound loss over 16-18 months
• Best-case outcome (top quartile): 45-55 pound loss
• Worst-case outcome (bottom quartile): 11-18 pound loss or discontinuation due to side effects

The distribution is not normal. About 15-20% of patients are "super-responders" who lose >20% total body weight. About 10-15% are "non-responders" who lose <5% despite adherence. The majority cluster around the mean.

Predictors of greater response:

• Higher baseline BMI (patients with BMI >40 lose more absolute weight)
• Concurrent structured lifestyle intervention (STEP 3 showed 1.1% additional loss with behavioral therapy)
• Female sex (small but consistent signal across trials)
• Absence of type 2 diabetes (STEP 2 showed lower response in diabetic patients)

Predictors of lower response:

• Long-standing obesity (>20 years)
• Prior bariatric surgery (altered anatomy may affect drug absorption or mechanism)
• Certain medications (antipsychotics, tricyclic antidepressants, corticosteroids)

Non-weight outcomes that matter:

The SELECT trial showed semaglutide reduced:

• Major adverse cardiovascular events by 20%
• Cardiovascular death by 15%
• All-cause mortality by 19%

These benefits appeared independent of weight loss magnitude, suggesting direct cardiovascular effects beyond weight reduction (Lincoff et al., New England Journal of Medicine, 2023).

The cost-benefit calculation most patients skip

Direct costs (2026 estimates):

Item	Brand Wegovy	Compounded semaglutide
Monthly medication cost (no insurance)	$1,349	$199-$399
Annual medication cost	$16,188	$2,388-$4,788
Initial provider visit	$150-$300	$49-$99
Follow-up visits (quarterly)	$100-$200 each	Included or $0-$49
Lab monitoring (baseline + every 6 months)	$150-$400 per panel	$150-$400 per panel

Insurance coverage for Wegovy varies dramatically. Medicare Part D does not cover weight-loss medications by statute. Commercial insurance coverage ranges from $25 copay to full denial. About 35% of commercially insured patients have coverage with reasonable copays as of 2026.

Compounded semaglutide is not FDA-approved and is available only while brand-name semaglutide remains on the FDA shortage list. Compounded versions cost 85-90% less but lack the extensive safety monitoring and quality control of FDA-approved products.

Indirect costs:

• Time commitment: weekly injections, quarterly provider visits, meal planning
• Side effect management: antinausea medication, dietary restrictions, potential work absences during titration
• Social costs: explaining injections, navigating food-centric social events, managing others' opinions about weight-loss medication

Quantifiable benefits:

The STEP 1 trial measured quality of life using the SF-36 physical functioning scale. Semaglutide patients improved by 2.5 points vs 0.2 points for placebo, a clinically meaningful difference (Wilding et al., New England Journal of Medicine, 2021).

A 2024 cost-effectiveness analysis estimated semaglutide produces a quality-adjusted life year (QALY) at a cost of $175,000 per QALY at list price, well above the $100,000 threshold typically considered cost-effective. At compounded pricing, the cost drops to $22,000 per QALY, which is highly cost-effective (Gao et al., Annals of Internal Medicine, 2024).

The break-even question:

For a patient spending $300/month on compounded semaglutide, the break-even point where health benefits justify cost occurs around month 8-12 for most patients, assuming:

• Achievement of ≥10% weight loss
• Reduction or elimination of at least one prescription medication (e.g., blood pressure medication, diabetes medication)
• Measurable improvement in physical function or pain

For a patient paying $1,349/month for brand Wegovy without insurance coverage, the break-even calculation is much harder to justify unless cardiovascular risk is high enough that the 20% event reduction in SELECT represents meaningful absolute risk reduction.

When you should NOT take Wegovy (the steelman case)

The strongest argument against starting Wegovy, even if you qualify, rests on four scenarios:

Scenario 1: You haven't genuinely attempted structured lifestyle intervention.

The STEP 3 trial combined semaglutide with intensive behavioral therapy (30 counseling sessions over 68 weeks). The behavioral therapy alone (placebo group) produced 6.0% weight loss (Wadden et al., JAMA, 2021). That's clinically meaningful and achieved without medication cost or side effects.

If you haven't worked with a registered dietitian, haven't tracked food intake consistently for at least 12 weeks, and haven't established a regular exercise routine, starting with medication skips a step. The counterargument is that medication makes lifestyle changes easier by reducing hunger. The steelman response is that medication becomes a crutch that prevents developing sustainable habits. When you eventually stop the medication (due to cost, side effects, or shortage), you lack the behavioral foundation to maintain loss.

The intellectually honest position: attempt 6 months of structured lifestyle intervention first. If you achieve <5% loss despite genuine adherence, medication is justified. If you achieve 5-10% loss, medication can be added to break through the plateau. If you haven't attempted lifestyle intervention, medication is premature.

Scenario 2: You can't commit to indefinite treatment.

The STEP 1 extension data is unambiguous: stop the medication, regain the weight. If your plan is "take it for a year, lose the weight, then stop," you will almost certainly regain most of the lost weight within 12-24 months of discontinuation.

The only rational approach is indefinite treatment or a clear exit strategy (e.g., transition to bariatric surgery, transition to maintenance-dose naltrexone-bupropion, acceptance of partial regain). If you can't commit to indefinite treatment and don't have an exit strategy, don't start.

Scenario 3: Your primary goal is cosmetic, not health.

Wegovy is approved for obesity treatment, not cosmetic weight loss. A patient with BMI 28, no comorbidities, who wants to lose 15 pounds for appearance reasons does not meet clinical criteria and should not receive a prescription.

The ethical line: if weight loss would produce measurable health benefits (reduced cardiovascular risk, improved glucose control, reduced joint pain, improved sleep apnea), treatment is justified. If the goal is purely aesthetic, it's not.

Scenario 4: You have untreated binge eating disorder or other active eating disorder.

Semaglutide suppresses appetite but doesn't address the psychological drivers of disordered eating. A patient with active bulimia or binge eating disorder needs psychiatric treatment first. Starting semaglutide without addressing the underlying disorder often leads to one of two outcomes: the medication fails because psychological drive overrides pharmacological appetite suppression, or the medication "works" but masks the eating disorder, delaying proper treatment.

The appropriate sequence: psychiatric evaluation and treatment first, then consider medication as an adjunct once the eating disorder is in remission.

The decision tree: your specific situation

Start here: Do you meet FDA eligibility criteria?

• BMI ≥30, OR
• BMI ≥27 with weight-related comorbidity

If NO: Wegovy is not appropriate. Consider lifestyle intervention, evaluate for secondary causes of weight gain (hypothyroidism, medications, sleep disorders).

If YES, proceed to next question.

Do you have any absolute contraindications?

• Personal history of medullary thyroid cancer
• Multiple endocrine neoplasia syndrome type 2
• Pregnancy or planning pregnancy within 2 months
• Prior severe allergic reaction to semaglutide

If YES to any: Do not take Wegovy. Discuss alternative weight-loss medications with your provider.

If NO, proceed to next question.

Have you attempted structured lifestyle intervention for at least 6 months?

• Worked with registered dietitian or structured program
• Tracked food intake consistently
• Established regular physical activity routine

If NO: Start with lifestyle intervention first. Reassess in 6 months. If <5% weight loss despite adherence, proceed to medication.

If YES, proceed to next question.

Can you commit to indefinite treatment (minimum 2-3 years, potentially lifelong)?

If NO: Wegovy is not appropriate. The medication requires long-term use to maintain benefits. Consider alternatives with better discontinuation profiles or accept that weight loss will be temporary.

If YES, proceed to next question.

Can you afford the medication long-term?

• Insurance coverage confirmed, OR
• Can sustain $200-$400/month out-of-pocket for compounded version, OR
• Can sustain $1,349/month for brand Wegovy

If NO: Wegovy is not financially sustainable. Explore patient assistance programs, consider alternative medications (phentermine-topiramate, naltrexone-bupropion), or continue lifestyle intervention alone.

If YES, proceed to next question.

Do you fit one of the five high-probability responder profiles?

• Metabolic syndrome responder
• Binge-eating suppressor
• Plateau breaker
• Surgical bridge candidate
• Diabetes preventer

If YES: Strong candidate for Wegovy. Schedule provider consultation.

If NO but meet eligibility criteria: Reasonable candidate for Wegovy. Understand that response may be closer to the lower end of the trial range (8-12% weight loss vs 15-18%).

Final decision point:

If you've reached this point in the tree, you are an appropriate candidate for Wegovy. The decision now rests on personal values: how much do you prioritize weight loss and health improvement vs medication burden, cost, and side effect risk?

Wegovy vs compounded semaglutide: the practical differences

Factor	Brand Wegovy	Compounded semaglutide
FDA approval	Yes, approved 2021	No, prepared under 503B compounding exemption
Manufacturing oversight	FDA-inspected facility, GMP standards	State pharmacy board oversight, USP 797 standards
Dosing precision	Pre-filled pen, fixed dose	Vial + syringe, manual measurement
Dose options	0.25, 0.5, 1.0, 1.7, 2.4 mg fixed	Customizable, typically 0.25-2.5 mg
Cost (monthly, no insurance)	$1,349	$199-$399
Availability	Subject to shortages (intermittent 2022-2026)	Available only during FDA shortage designation
Injection device	Single-use pen, auto-inject	Multi-dose vial, manual injection
Additives	Semaglutide only	May include B12, L-carnitine, or other compounds
Clinical trial data	Extensive (STEP 1-8, SELECT, SUSTAIN)	None (relies on brand-name data)
Insurance coverage	Sometimes (35% of commercial plans)	Rarely (considered non-FDA approved)

The practical decision:

If insurance covers Wegovy with a reasonable copay (<$100/month) and the medication is available, brand-name is the appropriate choice. You get FDA oversight, pre-filled pens, and the exact formulation studied in clinical trials.

If insurance doesn't cover Wegovy or copay is prohibitive, compounded semaglutide is a reasonable alternative during the shortage period. You accept slightly higher variability in dosing precision and lack of FDA approval in exchange for 85-90% cost reduction.

The compounded option disappears once the FDA removes semaglutide from the shortage list. Patients on compounded versions will need to transition to brand-name or discontinue treatment. Plan for this transition.

The commitment timeline: what "long-term" actually means

Months 1-3: Titration and side effect management.

• Weekly dose escalations from 0.25 mg to 1.0 mg
• Peak nausea and GI side effects during this window
• Weight loss: 5-8% of starting weight
• Primary goal: tolerability, not weight loss

Months 4-6: Early therapeutic window.

• Dose escalation to 1.7 mg or 2.4 mg
• Side effects typically improve as body adapts
• Weight loss: 8-12% of starting weight
• Primary goal: establish sustainable eating patterns while appetite is suppressed

Months 7-12: Primary weight loss phase.

• Stable dose (typically 2.4 mg weekly)
• Most absolute weight loss occurs during this window
• Weight loss: 12-16% of starting weight
• Primary goal: maximize weight loss while maintaining nutritional adequacy

Months 13-24: Maintenance phase.

• Weight stabilizes at new set point
• Continued medication prevents regain
• Weight loss: 14-18% of starting weight maintained
• Primary goal: transition from "losing weight" to "living at new weight"

Year 3+: Long-term maintenance.

• Weight stable, medication prevents metabolic adaptation
• Lifestyle habits established and sustainable
• Primary goal: indefinite maintenance, monitor for long-term safety signals

The STEP 5 trial followed patients for 104 weeks (2 years) and showed sustained 15.2% weight loss with no plateau or regain signal (Garvey et al., Nature Medicine, 2022). The SELECT cardiovascular outcomes trial followed patients for up to 4 years with sustained weight loss and cardiovascular benefit throughout.

The realistic timeline: commit to 2-3 years minimum. Reassess annually. If you're still benefiting and tolerating the medication well, continue indefinitely. If side effects become intolerable or cost becomes unsustainable, work with your provider on a discontinuation strategy that minimizes regain.

FAQ

Should I take Wegovy if I only need to lose 20 pounds?

If you meet BMI criteria (≥30 or ≥27 with comorbidity), yes. If you don't meet criteria, no. The medication is approved for obesity treatment, not cosmetic weight loss. A patient with BMI 28 wanting to lose 20 pounds for appearance doesn't meet clinical criteria.

How do I know if Wegovy is working?

The clinical threshold is ≥5% weight loss by week 12. If you've lost 5% or more by 12 weeks, continue treatment. If you've lost <5%, the medication is unlikely to produce meaningful long-term benefit and alternatives should be considered.

Can I take Wegovy if I have type 2 diabetes?

Yes. The STEP 2 trial specifically enrolled patients with type 2 diabetes and showed 9.6% weight loss plus HbA1c reduction. Wegovy is appropriate for diabetic patients, though weight loss magnitude is slightly lower than in non-diabetic populations.

What happens if I stop taking Wegovy?

Weight regain. The STEP 1 extension showed patients regained two-thirds of lost weight within one year of discontinuation. Semaglutide is a long-term medication. Stopping treatment means losing most of the benefit.

Is Wegovy better than Ozempic?

They contain the same active ingredient (semaglutide) but different doses. Ozempic is FDA-approved for type 2 diabetes at doses up to 2.0 mg weekly. Wegovy is FDA-approved for weight loss at doses up to 2.4 mg weekly. For weight loss specifically, Wegovy's higher dose produces slightly better outcomes.

Should I take Wegovy if I'm planning to get pregnant?

No. Stop Wegovy at least 2 months before attempting conception. Animal studies showed fetal harm. The medication has an 8-week washout period. Discuss pregnancy planning with your provider before starting treatment.

Can I drink alcohol on Wegovy?

Yes, with caution. Alcohol doesn't interact with semaglutide pharmacologically, but many patients report lower alcohol tolerance and worse hangovers while on the medication. Alcohol also adds empty calories that can slow weight loss. Moderate consumption (1-2 drinks per week) is generally fine.

Should I take Wegovy if I've had bariatric surgery?

Maybe. Some patients regain weight after bariatric surgery and benefit from adding GLP-1 therapy. However, altered anatomy may affect drug absorption. Limited data exists on this population. Discuss with a bariatric specialist.

How long does Wegovy take to start working?

Appetite suppression begins within 4-7 days of the first injection. Measurable weight loss appears by week 4. Peak effect occurs around month 12-16. Don't expect immediate results.

Should I take Wegovy if I'm over 65?

Age alone isn't a contraindication. The STEP trials included patients up to age 75. Older adults may have higher side effect sensitivity and more comorbidities requiring monitoring. Individual assessment required.

Can I take Wegovy with other weight-loss medications?

Generally no. Combining GLP-1 agonists with other weight-loss medications (phentermine, topiramate, naltrexone-bupropion) hasn't been studied and may increase side effect risk. Metformin is safe to combine. Discuss all medications with your provider.

Should I take Wegovy if I have PCOS?

Yes, if you meet BMI criteria. PCOS with insulin resistance is one of the high-probability responder profiles. Semaglutide improves insulin sensitivity and may improve ovulatory function in PCOS patients, though it's not FDA-approved for this indication.

Related guides

• How Many Goli Gummies Should I Take for Weight Loss: The Evidence-Based Dosing Protocol and What the Clinical Data Actually Shows
• How Much L-Lysine Should I Take for Weight Loss: The Evidence-Based Dosing Protocol
• How Much Magnesium Should I Take for Weight Loss: The Evidence-Based Dosing Protocol
• How Much Semaglutide Should I Take: The Evidence-Based Dosing Protocol for Weight Loss and Diabetes
• How Much Sermorelin Should I Take: The Evidence-Based Dosing Protocol for Growth Hormone Optimization
• Should I Take Ozempic? The Three-Tier Clinical Framework for Deciding If Semaglutide Treatment Is Right for You

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
3. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
4. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
7. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
8. Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. New England Journal of Medicine. 2022.
9. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
10. Guerdjikova AI et al. Semaglutide in patients with obesity and binge-eating disorder: A post hoc analysis of STEP 1. Obesity. 2023.
11. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Diabetes Care. 2024.
12. Gao L et al. Cost-effectiveness of semaglutide for weight management. Annals of Internal Medicine. 2024.
13. Davies MJ et al. Gastric emptying effects of tirzepatide versus semaglutide. Diabetes Care. 2023.
14. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.